Macrogenics Inc. (MGNX) intrinsic value & 10-year financials

Macrogenics Inc. (MGNX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 5.6% a year to $149.5M, with an average return on invested capital of 134.3%.

Graham intrinsic value
—
Share price (Oct 17, 2026)
$3.25
Market cap
$205.3M
Revenue (FY2025)
$149.5M
Revenue growth (10-yr CAGR)
5.6%
ROIC (10-yr avg)
134.3%
Free cash flow (FY2025)
-$83.0M

MGNX 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $149.5M -$74.6M -$1.18 -$83.0M -48.7% 3415.7%
FY2024 $150.0M -$67.0M -$1.07 -$72.1M -73.7% -464.0%
FY2023 $58.7M -$9.1M -$0.15 -$80.0M -286.4% -231.9%
FY2022 $151.9M -$119.8M -$1.95 -$90.6M -79.9% -121.3%
FY2021 $77.4M -$202.1M -$3.37 -$150.0M -261.9% -146.4%
FY2020 $104.9M -$129.7M -$2.47 -$117.8M -125.0% -96.5%
FY2019 $64.2M -$151.8M — -$138.6M -276.0% -229.4%
FY2018 $60.1M -$171.5M — -$178.2M -284.8% -752.6%
FY2017 $157.7M -$19.6M — -$15.0M -14.0% -7.8%
FY2016 $91.9M -$58.5M — -$55.1M -65.3% -22.3%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

MACROGENICS INC has demonstrated mature, steady growth, with revenue compounding at 5.6% annually over the past decade.

MACROGENICS INC has historically struggled to out-earn its cost of capital, averaging just -37.7% ROIC.

MACROGENICS INC has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, MACROGENICS INC is modeled at 5.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-19.97 per share.

MGNX stock: frequently asked questions

What is the intrinsic value of Macrogenics Inc. (MGNX) stock?

Graham's formula only works with positive earnings. Macrogenics Inc. reported diluted EPS of -$1.18 in fiscal 2025, so no Graham value is shown. The 10-year table shows revenue and cash-flow trends instead.

How fast has Macrogenics Inc. grown?

Revenue went from $91.9M in fiscal 2016 to $149.5M in fiscal 2025, a compound annual growth rate of 5.6%. Net income was -$74.6M in fiscal 2025.

Does Macrogenics Inc. generate free cash flow?

Macrogenics Inc. generated -$83.0M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 0 of the last 10 reported years.

What is MGNX's return on invested capital?

Average ROIC over the last 10 fiscal years was 134.3%, and average return on equity was -48.6%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this MGNX data come from?

From Macrogenics Inc.'s annual 10-K filings on SEC EDGAR, most recently filed May 13, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks